Education
About Us
Working with TipRanks
Follow Us
Collegium Pharmaceutical (COLL)
NASDAQ:COLL
Earnings Data
Report Date
Feb 19, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
2.14Last Year’s EPS
1.77Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Collegium Pharmaceuticals reported a strong quarter with record revenues and growth across key product lines, particularly Jornay PM and the pain portfolio. The company has shown effective strategic capital deployment and increased financial guidance for 2025, indicating confidence in continued growth. However, there are some concerns regarding gross to net variability and the delayed impact of sales force expansion.Company Guidance
Record Quarterly Net Revenue
Collegium Pharmaceuticals achieved record quarterly net revenue of $209.4 million, which is a 31% year-over-year increase.
Strong Growth in Jornay PM
Jornay PM generated a record $41.8 million in net revenue with a prescription growth of 20% year-over-year.
Pain Portfolio Revenue Growth
Net revenue from the pain portfolio grew to a record $167.6 million, up 11% year-over-year.
Adjusted EBITDA Growth
Adjusted EBITDA grew 27% year-over-year to $133 million.
Increased Financial Guidance for 2025
Collegium raised its 2025 financial guidance, expecting total revenue growth of approximately 24% year-over-year.
Strategic Capital Deployment
The company repaid $16.1 million of debt and ended the third quarter with $285.9 million in cash, cash equivalents, and marketable securities.
Expansion of Sales Force
The company expanded its ADHD sales force to approximately 180 representatives, targeting an increased number of prescribers.
COLL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
COLL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | $35.85 | $40.66 | +13.42% |
Aug 07, 2025 | $29.75 | $32.94 | +10.72% |
May 08, 2025 | $27.27 | $28.89 | +5.94% |
Feb 27, 2025 | $28.42 | $29.05 | +2.22% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Collegium Pharmaceutical (COLL) report earnings?
Collegium Pharmaceutical (COLL) is schdueled to report earning on Feb 19, 2026, TBA (Confirmed).
What is Collegium Pharmaceutical (COLL) earnings time?
Collegium Pharmaceutical (COLL) earnings time is at Feb 19, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is COLL EPS forecast?
COLL EPS forecast for the fiscal quarter 2025 (Q4) is 2.14.